Join
Live feed
·
PRReleasevia Quantisnow
Incyte Corp. logo

Results from Incyte's Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival

ByQuantisnow·Wall Street's wire, on your screen.
INCY· Incyte Corp.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track INCY (Incyte Corp.) and more on Quantisnow.